Bay Pharma, founded with a strong vision for the future of pharmaceutical innovation, is a pioneering supplier of pharmaceutical-grade therapeutic vaporised nicotine products. Our company operates at the intersection of cutting-edge research and rigorous safety standards, ensuring our offerings are always of the highest calibre. With an unwavering commitment to health, safety, and quality, we are proudly compliant with the Therapeutic Goods Administration (TGO-110) Standards, a testament to our dedication to excellence.

Our product portfolio, robustly designed to meet the needs of our Australian customer base, centres on vaporised nicotine products formulated to the highest pharmaceutical standards. Leveraging scientific knowledge and advanced technologies, we deliver nicotine solutions that meet the rigorous demands of the pharmaceutical industry.

It's critical to note that Bay Pharma is wholly independent. We stand apart from the tobacco industry and are committed to establishing a health-focused future that rises above traditional nicotine delivery methods.

Bay Pharma manufactures and distributes NVP products with the primary focus of enabling 2.2 million Australian smokers reduce the harms caused by smoking and to quit.

Over 70% of Australian smokers would like to quit but are either unable or unwilling. Bay Pharma offers viable alternatives that allow smokers to reduce the harms associated with smoking. 

Bay Pharma products are manufactured the highest quality standards and exceeds the requirement in Australia. 

We recognise that while these products can help achieve the goal of a smoke-free Australia, they should not be accessible to youth or non-smokers. 

The team at Bay Pharma is committed to helping improve smoking cessation rates nationwide and will continue to work in collaboration with medical, scientific and public health stakeholders to ensure that we stay at the very forefront of therapeutic NVP technology and innovation.

BayPharma

Org chart

Teams

Offices